{
    "clinical_study": {
        "@rank": "148168", 
        "arm_group": [
            {
                "arm_group_label": "AVI\u00ae Arsenic trioxide drug eluting stent", 
                "arm_group_type": "Experimental", 
                "description": "Study group: Arsenic trioxide drug eluting stent delivery system (AVI\u00ae)"
            }, 
            {
                "arm_group_label": "Firebird2\u00ae sirolimus eluting stent system", 
                "arm_group_type": "Active Comparator", 
                "description": "Control group: sirolimus eluting cobalt-chromium alloy stent system(Firebird 2\u00ae)"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate The Safety and Efficacy of 'AVI' Stent Comparing with Firebird2\u00ae For Treating\n      Coronary Revascularization."
        }, 
        "brief_title": "To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2\u00ae For Treating Coronary Revascularization", 
        "completion_date": {
            "#text": "August 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ischemic Heart Disease", 
            "Myocardial Ischemia", 
            "Coronary Disease", 
            "Acute Coronary Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Myocardial Ischemia", 
                "Coronary Artery Disease", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Ischemia", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is a Prospective, Open-lable, Multi-center, Randomized trial. 2000 primary\n      coronary artery disease patients will be enrolled with a 1:1 randomization\n      ratio(AVI:1000,Firebird 2:1000) at approximately 40 sites, Subject follow-up be at 30 days,\n      6 months, 9 months, 12 months, 2-5 years after procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient must be at least 18 years of age.\n\n          2. Ischemic heart symptom and/or myocardial ischemia, include chronic stable/unstable\n             coronary artery disease or acute coronary syndrome(ST elevated MI and Non-ST elevated\n             MI)\n\n          3. At least one lesion diameter  stenosis(DS) \u226570\uff05, reference vessel diameter  between\n             \u22652.5mm, and \u22643.5mm.\n\n          4. If the subject has multiple vessel lesions, the implanted stents must be the same\n             brand. The staged procedure only be allowed  within 3 months after procedure, the\n             implanted stent must be the same brand stent as the index procedure.\n\n          5. Subject has no CABG contraindication.\n\n          6. Subject or legal representative is informed the property of the study, understand the\n             stipulations in the protocol, ensure the compliance and sign the ICF.\n\n        Exclusion Criteria:\n\n          1. Pregnant or nursing patients and those who plan to become pregnant up to  1 year post\n             index procedure.\n\n          2. Subject has a tendency to bleeding or coagulation disorders, or has contraindication\n             of antiplatelet and/or anticoagulant therapy, or can't accept the continue DAPT\n             within 6 months.\n\n          3. Poor compliance or expectation of life less than 1 year.\n\n          4. Implanted any brand stent in the same target vessel within 1 year.\n\n          5. Left Ventricular Ejection Fraction (LVEF) of \uff1c30\uff05\n\n          6. Cardiogenic shock or haemodynamics  abnormal, needs inotropic agents or mechanical\n             support.\n\n          7. The subject is allergic to asprin, heparin, clopidogrel/ticlopidine, stainless steel\n             alloy, Arsenic trioxide, sirolimus, styrene-butene-styrene or polylactic acid(PLA)\n             polymer and contrast agent.\n\n          8. Severe tortuous and/or heavy calcification lesion.\n\n          9. Two or more proximal chronic total occlusion lesion.\n\n         10. Bifurcation lesions with double stents.\n\n         11. The subject has multi vessel lesions but can not be implanted the same brand stents\n\n         12. The subject that the investigator considers he/she was unfit to implant the AVI\n             stents and Firebird 2 stents.\n\n         13. The subject attended other drug/device study or in the follow-up period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133287", 
            "org_study_id": "PERFECT-II"
        }, 
        "intervention": [
            {
                "arm_group_label": "AVI\u00ae Arsenic trioxide drug eluting stent", 
                "intervention_name": "AVI\u00ae Arsenic trioxide drug eluting stent delivery system", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Firebird2\u00ae sirolimus eluting stent system", 
                "intervention_name": "Firebird2\u00ae sirolimus eluting stent system", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Arsenic trioxide", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100034"
                }, 
                "name": "Peking University First Hospital"
            }, 
            "investigator": {
                "last_name": "Yong Huo, Prof.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multi-center, Randomized Trial To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2\u00ae For Treating Coronary Revascularization", 
        "overall_contact": {
            "email": "iamsinoclinical@126.com", 
            "last_name": "Meixiang Chai", 
            "phone": "86-10-58660666"
        }, 
        "overall_official": {
            "affiliation": "Peking University First Hospital", 
            "last_name": "Yong Huo, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ischemia-driven target lesion failure(iTLF), including cardiac death, target vessel related MI(Q wave and Non-Q wave) and ischemic-driven target lesion revascularization(iTLR)", 
            "safety_issue": "Yes", 
            "time_frame": "at 12 months post procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133287"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Beijing AmsinoMed Medical Device Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing AmsinoMed Medical Device Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}